Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2017 (2017), Article ID 4385161, 7 pages
https://doi.org/10.1155/2017/4385161
Clinical Study

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial

1Department of Gastroenterology, Nagano Red Cross Hospital, Nagano, Japan
2Department of Metabolic Regulation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
3Digestive Disease Center, Showa Inan General Hospital, Komagane, Japan
4Department of Gastroenterology, Aizawa Hospital, Matsumoto, Japan

Correspondence should be addressed to Masafumi Maruyama

Received 27 October 2016; Accepted 18 January 2017; Published 28 February 2017

Academic Editor: Michael Beyak

Copyright © 2017 Masafumi Maruyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. IARC, Schistosomes, Liver Flukes and Helicobacter pylori, vol. 61 of IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Lyon, France, 1994.
  2. C. De Martel, J. Ferlay, S. Franceschi et al., “Global burden of cancers attributable to infections in 2008: a review and synthetic analysis,” The Lancet Oncology, vol. 13, no. 6, pp. 607–615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Y.-C. Lee, T.-H. Chiang, C.-K. Chou et al., “Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis,” Gastroenterology, vol. 150, no. 5, pp. 1113e5–1124.e5, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Tsugawa, H. Suzuki, H. Saya et al., “Reactive oxygen species-induced autophagic degradation of helicobacter pylori CagA is specifically suppressed in cancer stem-like cells,” Cell Host and Microbe, vol. 12, no. 6, pp. 764–777, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. A. Valenzuela, J. Canales, A. H. Corvalán, and A. F. G. Quest, “Helicobacter pylori-induced inflammation and epigenetic changes during gastric carcinogenesis,” World Journal of Gastroenterology, vol. 21, no. 45, pp. 12742–12756, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Tatematsu, T. Tsukamoto, and T. Toyoda, “Effects of eradication of Helicobacter pylori on gastric carcinogenesis in experimental models,” Journal of Gastroenterology, vol. 42, no. 17, pp. 7–9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Gisbert and X. Calvet, “Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough,” Alimentary Pharmacology and Therapeutics, vol. 34, no. 11-12, pp. 1255–1268, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the maastricht IV/florence consensus report,” Gut, vol. 61, pp. 646–664, 2012. View at Google Scholar
  9. W. D. Chey and B. C. Y. Wong, “American College of Gastroenterology guideline on the management of Helicobacter pylori infection,” American Journal of Gastroenterology, vol. 102, no. 8, pp. 1808–1825, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Asaka, M. Kato, S.-I. Takahashi et al., “Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition,” Helicobacter, vol. 15, no. 1, pp. 1–20, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Y. Graham and A. Shiotani, “New concepts of resistance in the treatment of Helicobacter pylori infections,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 5, no. 6, pp. 321–331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Liou, C.-C. Chen, C.-Y. Chang et al., “Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial,” Gut, vol. 65, no. 11, pp. 1784–1792, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-M. Liou, C.-Y. Chang, M.-J. Chen et al., “The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors—a nationwide study,” PLoS ONE, vol. 10, no. 5, Article ID e0124199, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Liou, M. S. Wu, and J. T. Lin, “Treatment of Helicobacter pylori infection—where are we now?” Journal of Gastroenterology and Hepatology, vol. 31, pp. 1918–1926, 2016. View at Google Scholar
  15. G. Sachs, D. R. Scott, and Y. Wen, “Gastric infection by Helicobacter pylori,” Current Gastroenterology Reports, vol. 13, no. 6, pp. 540–546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Hori, A. Imanishi, J. Matsukawa et al., “1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl] -N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases,” Journal of Pharmacology and Experimental Therapeutics, vol. 335, no. 1, pp. 231–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Sakurai, Y. Mori, H. Okamoto et al., “Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects—a randomised open-label cross-over study,” Alimentary Pharmacology and Therapeutics, vol. 42, no. 6, pp. 719–730, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Echizen, “The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations,” Clinical Pharmacokinetics, vol. 55, no. 4, pp. 409–418, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Sakurai, A. Nishimura, G. Kennedy et al., “Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (Vonoprazan) doses in healthy male Japanese/non-Japanese subjects,” Clinical and Translational Gastroenterology, vol. 6, article e94, 2015. View at Google Scholar
  20. H. Jenkins, Y. Sakurai, A. Nishimura et al., “Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects,” Alimentary Pharmacology and Therapeutics, vol. 41, no. 7, pp. 636–648, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Murakami, Y. Sakurai, M. Shiino, N. Funao, A. Nishimura, and M. Asaka, “Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylorieradication: a phase III, randomised, double-blind study,” Gut, vol. 65, no. 9, pp. 1439–1446, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kawai, S. Takahashi, H. Suzuki et al., “Changes in the first line Helicobacter pylori eradication rates using the triple therapy—a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group),” Journal of Gastroenterology and Hepatology, vol. 29, supplement 4, pp. 29–32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Nishizawa, T. Maekawa, N. Watanabe et al., “Clarithromycin versus metronidazole as first-line helicobacter pylori eradication,” Journal of Clinical Gastroenterology, vol. 49, no. 6, pp. 468–471, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Furuta, N. Shirai, M. Sugimoto, A. Nakamura, A. Hishida, and T. Ishizaki, “Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies,” Drug Metabolism and Pharmacokinetics, vol. 20, no. 3, pp. 153–167, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Suzuki, T. Gotoda, C. Kusano, K. Iwatsuka, and M. Moriyama, “The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy,” American Journal of Gastroenterology, vol. 111, no. 7, pp. 949–956, 2016. View at Publisher · View at Google Scholar · View at Scopus